Published in Br J Cancer on May 01, 1996
Medical history, lifestyle, family history, and occupational risk factors for follicular lymphoma: the InterLymph Non-Hodgkin Lymphoma Subtypes Project. J Natl Cancer Inst Monogr (2014) 1.01
Current understanding of lifestyle and environmental factors and risk of non-hodgkin lymphoma: an epidemiological update. J Cancer Epidemiol (2012) 0.95
Blood transfusions and the subsequent risk of hematologic malignancies. Transfusion (2010) 0.93
B-cell lymphoma in retrieved femoral heads: a long term follow up. BMC Musculoskelet Disord (2009) 0.91
Blood transfusion, anesthesia, surgery and risk of non-Hodgkin lymphoma in a population-based case-control study. Int J Cancer (2008) 0.90
Monoclonal B-cell lymphocytosis and early-stage chronic lymphocytic leukemia: diagnosis, natural history, and risk stratification. Blood (2015) 0.86
Cancer risk among 21st century blood transfusion recipients. Ann Oncol (2017) 0.75
Reversibility of lymphomas and lymphoproliferative lesions developing under cyclosporin-steroid therapy. Lancet (1984) 5.74
Incidence of non-Hodgkin lymphoma in kidney and heart transplant recipients. Lancet (1994) 3.56
Beneficial effect of autologous blood transfusion on infectious complications after colorectal cancer surgery. Lancet (1993) 3.45
Updated Kiel classification for lymphomas. Lancet (1988) 3.25
AIDS-associated non-Hodgkin lymphoma. Lancet (1991) 3.20
Biologic effects of leukocytes present in transfused cellular blood products. Blood (1994) 1.65
The increasing incidence of non-Hodgkin's lymphoma (NHL): the possible role of sunlight. Leuk Lymphoma (1994) 1.60
Transfusion history and cancer risk in older women. Ann Intern Med (1993) 1.07
Cancer morbidity in blood recipients--results of a cohort study. Eur J Cancer (1993) 1.04
Blood transfusion-induced suppression of cellular immunity in man. Hum Immunol (1980) 0.98
Increase in the incidence of non-Hodgkin's lymphomas: evidence for a recent sharp increase in France independent of AIDS. Br J Cancer (1994) 0.94
A search for unknown blood-borne oncogenic viruses. Int J Cancer (1994) 0.89
Immunologic effects of blood transfusion upon renal transplantation, tumor operations, and bacterial infections. Am J Surg (1986) 0.88
Gene-expression profiles in hereditary breast cancer. N Engl J Med (2001) 29.80
Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet (2003) 18.67
The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection. Ann Rheum Dis (2009) 8.37
Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet (2002) 6.12
Alcohol, tobacco and breast cancer--collaborative reanalysis of individual data from 53 epidemiological studies, including 58,515 women with breast cancer and 95,067 women without the disease. Br J Cancer (2002) 5.83
EUROCARE-3: survival of cancer patients diagnosed 1990-94--results and commentary. Ann Oncol (2003) 5.78
Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease. Eur Respir J (2003) 5.53
The Assessment of SpondyloArthritis International Society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general. Ann Rheum Dis (2010) 5.24
HABITS (hormonal replacement therapy after breast cancer--is it safe?), a randomised comparison: trial stopped. Lancet (2004) 4.40
The Assessment of SpondyloArthritis international Society (ASAS) handbook: a guide to assess spondyloarthritis. Ann Rheum Dis (2009) 4.37
Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. Eur Respir J (2003) 4.20
Randomised study of cognitive effects of iron supplementation in non-anaemic iron-deficient adolescent girls. Lancet (1996) 4.20
Prospective randomized trial comparing mitomycin, cisplatin, and protracted venous-infusion fluorouracil (PVI 5-FU) With epirubicin, cisplatin, and PVI 5-FU in advanced esophagogastric cancer. J Clin Oncol (2002) 3.98
The BOADICEA model of genetic susceptibility to breast and ovarian cancers: updates and extensions. Br J Cancer (2008) 3.87
The natural history of recovery for the healthcare provider "second victim" after adverse patient events. Qual Saf Health Care (2009) 3.79
Oral contraceptives and the risk of hereditary ovarian cancer. Hereditary Ovarian Cancer Clinical Study Group. N Engl J Med (1998) 3.60
Patient satisfaction after anaesthesia and surgery: results of a prospective survey of 10,811 patients. Br J Anaesth (2000) 3.46
Long-term pacing in sinus node disease: effects of stimulation mode on cardiovascular morbidity and mortality. Am Heart J (1988) 3.33
The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part I): classification of paper patients by expert opinion including uncertainty appraisal. Ann Rheum Dis (2009) 3.32
Predicting time to nursing home care and death in individuals with Alzheimer disease. JAMA (1997) 3.17
Effect of pregnancy on prognosis for young women with breast cancer. Lancet (1994) 2.92
Microdomains for neuron-glia interaction: parallel fiber signaling to Bergmann glial cells. Nat Neurosci (1999) 2.87
Single breath diffusing capacity in a representative sample of the population of Michigan, a large industrial state. Predicted values, lower limits of normal, and frequencies of abnormality by smoking history. Am Rev Respir Dis (1983) 2.83
Onset and rate of striatal atrophy in preclinical Huntington disease. Neurology (2004) 2.81
Motor disorder in Huntington's disease begins as a dysfunction in error feedback control. Nature (2000) 2.81
Magnetic resonance imaging examinations of the spine in patients with ankylosing spondylitis, before and after successful therapy with infliximab: evaluation of a new scoring system. Arthritis Rheum (2003) 2.78
Family history of breast and ovarian cancers and BRCA1 and BRCA2 mutations in a population-based series of early-onset breast cancer. J Natl Cancer Inst (2001) 2.74
Construct and concurrent validity of the Hopkins Verbal Learning Test-revised. Clin Neuropsychol (1999) 2.65
High frequency of multiple melanomas and breast and pancreas carcinomas in CDKN2A mutation-positive melanoma families. J Natl Cancer Inst (2000) 2.41
Surgical margins, local recurrence and metastasis in soft tissue sarcomas: 559 surgically-treated patients from the Scandinavian Sarcoma Group Register. Eur J Cancer (2000) 2.34
Soft-tissue sarcomas and exposure to chemical substances: a case-referent study. Br J Ind Med (1981) 2.34
A Bayesian approach for estimating values for prevalence and diagnostic test characteristics of porcine cysticercosis. Int J Parasitol (2004) 2.34
Moderate frequency of BRCA1 and BRCA2 germ-line mutations in Scandinavian familial breast cancer. Am J Hum Genet (1997) 2.33
Prediction of a major clinical response (BASDAI 50) to tumour necrosis factor alpha blockers in ankylosing spondylitis. Ann Rheum Dis (2004) 2.26
Tumour necrosis factor blockers do not increase overall tumour risk in patients with rheumatoid arthritis, but may be associated with an increased risk of lymphomas. Ann Rheum Dis (2005) 2.25
Survival of BRCA1 breast and ovarian cancer patients: a population-based study from southern Sweden. J Clin Oncol (1998) 2.24
Indicators of prognosis in node-negative breast cancer. N Engl J Med (1990) 2.23
New criteria for inflammatory back pain in patients with chronic back pain: a real patient exercise by experts from the Assessment of SpondyloArthritis international Society (ASAS). Ann Rheum Dis (2009) 2.22
Long-term efficacy and safety of infliximab in the treatment of ankylosing spondylitis: an open, observational, extension study of a three-month, randomized, placebo-controlled trial. Arthritis Rheum (2003) 2.20
Functional analysis of BRCA1 C-terminal missense mutations identified in breast and ovarian cancer families. Hum Mol Genet (2001) 2.19
Pretreatment prognostic factors and scoring system in 407 small-cell lung cancer patients. Int J Cancer (1987) 2.18
Randomized phase II study of two gemcitabine schedules for patients with impaired performance status (Karnofsky performance status </= 70) and advanced non-small-cell lung cancer. J Clin Oncol (2005) 2.17
Is the use of sunscreens a risk factor for malignant melanoma? Melanoma Res (1995) 2.11
Histone H3 phosphorylation and expression of cyclins A and B1 measured in individual cells during their progression through G2 and mitosis. Cytometry (1998) 2.11
Histopathological risk factors for ipsilateral breast events after breast conserving treatment for ductal carcinoma in situ of the breast--results from the Swedish randomised trial. Eur J Cancer (2006) 2.09
Steroid receptors in hereditary breast carcinomas associated with BRCA1 or BRCA2 mutations or unknown susceptibility genes. Cancer (1998) 2.06
Multiple ionization of atom clusters by intense soft X-rays from a free-electron laser. Nature (2002) 2.06
Atrial versus ventricular pacing in sinus node disease: a treatment comparison study. Am Heart J (1986) 2.05
Prevalence of disease among vinyl chloride and polyvinyl chloride workers. Ann N Y Acad Sci (1975) 2.04
Distinct somatic genetic changes associated with tumor progression in carriers of BRCA1 and BRCA2 germ-line mutations. Cancer Res (1997) 2.03
Enkephalin-like immunoreactivity in gland cells and nerve terminals of the adrenal medulla. Neuroscience (1978) 2.01
Time-dependent motor memory processes in amnesic subjects. J Neurophysiol (1998) 1.99
Association between executive attention and physical functional performance in community-dwelling older women. J Gerontol B Psychol Sci Soc Sci (1999) 1.98
Cartilage oligomeric matrix protein shows high affinity zinc-dependent interaction with triple helical collagen. J Biol Chem (1998) 1.94
Psychological costs and benefits of predictive testing for Huntington's disease. Am J Med Genet (1994) 1.94
Nonsteroidal anti-inflammatory drugs in Alzheimer's disease. Neurology (1995) 1.92
APOE epsilon 4 allele predicts faster cognitive decline in mild Alzheimer disease. Neurology (2008) 1.91
Breast and ovarian cancer risks to carriers of the BRCA1 5382insC and 185delAG and BRCA2 6174delT mutations: a combined analysis of 22 population based studies. J Med Genet (2005) 1.91
Risk of cancer among offspring of childhood-cancer survivors. Association of the Nordic Cancer Registries and the Nordic Society of Paediatric Haematology and Oncology. N Engl J Med (1998) 1.87
Efficacy of sulfasalazine in patients with inflammatory back pain due to undifferentiated spondyloarthritis and early ankylosing spondylitis: a multicentre randomised controlled trial. Ann Rheum Dis (2006) 1.86
Self-selection in predictive testing for Huntington's disease. Am J Med Genet (1994) 1.84
Blue babies and nitrate-contaminated well water. Environ Health Perspect (2000) 1.82
Tumour biological features of BRCA1-induced breast and ovarian cancer. Eur J Cancer (1997) 1.82
Nationwide cerebrovascular disease morbidity study. Stroke (1972) 1.82
Persistent clinical response to the anti-TNF-alpha antibody infliximab in patients with ankylosing spondylitis over 3 years. Rheumatology (Oxford) (2005) 1.82
Quality of life in patients with Alzheimer's disease as reported by patient proxies. J Am Geriatr Soc (1996) 1.78
Familial testicular cancer in Norway and southern Sweden. Br J Cancer (1996) 1.76
Use of sunbeds or sunlamps and malignant melanoma in southern Sweden. Am J Epidemiol (1994) 1.74
Dementia in hippocampal sclerosis resembles frontotemporal dementia more than Alzheimer disease. Neurology (2004) 1.74
Basal ganglia volume and proximity to onset in presymptomatic Huntington disease. Arch Neurol (1996) 1.74
Apolipoprotein E genotype and rate of decline in probable Alzheimer's disease. Arch Neurol (1996) 1.74
Covalent attachment of proteins to polysaccharide carriers by means of benzoquinone. Biochim Biophys Acta (1975) 1.73
Age-related dopamine D2/D3 receptor loss in extrastriatal regions of the human brain. Neurobiol Aging (2000) 1.71
The General Medical Health Rating: a bedside global rating of medical comorbidity in patients with dementia. J Am Geriatr Soc (1999) 1.71
Founding BRCA1 mutations in hereditary breast and ovarian cancer in southern Sweden. Am J Hum Genet (1996) 1.69
Rate of caudate atrophy in presymptomatic and symptomatic stages of Huntington's disease. Mov Disord (2000) 1.67
Risk of cutaneous malignant melanoma in relation to use of sunbeds: further evidence for UV-A carcinogenicity. Br J Cancer (2000) 1.67
Somatic deletions in hereditary breast cancers implicate 13q21 as a putative novel breast cancer susceptibility locus. Proc Natl Acad Sci U S A (2000) 1.66
Longitudinal study of effects of patient characteristics on direct costs in Alzheimer disease. Neurology (2006) 1.65
Response after withdrawal of tamoxifen and progestogens in advanced breast cancer. Ann Oncol (1992) 1.65
Quality of life in dementia patients in long-term care. Int J Geriatr Psychiatry (2000) 1.64
The course of psychopathologic features in mild to moderate Alzheimer disease. Arch Gen Psychiatry (1997) 1.63
Epicardial right atrial free wall mapping in chronic atrial fibrillation. Documentation of repetitive activation with a focal spread--a hitherto unrecognised phenomenon in man. Eur Heart J (1997) 1.63
Clinical factors associated with the non-utilization of an anaesthesia incident reporting system. Br J Anaesth (2011) 1.61
Reduced basal ganglia volume associated with the gene for Huntington's disease in asymptomatic at-risk persons. Neurology (1994) 1.61
Motor signs predict poor outcomes in Alzheimer disease. Neurology (2005) 1.60
Age at onset of Alzheimer's disease: relation to pattern of cognitive dysfunction and rate of decline. Neurology (1994) 1.60
Infliximab treatment of severe ankylosing spondylitis: one-year followup. Arthritis Rheum (2001) 1.58
Rapid ischemic cell death in immature oligodendrocytes: a fatal glutamate release feedback loop. J Neurosci (2000) 1.56
Reduced basal ganglia blood flow and volume in pre-symptomatic, gene-tested persons at-risk for Huntington's disease. Brain (1999) 1.56
Analysing chronic spinal changes in ankylosing spondylitis: a systematic comparison of conventional x rays with magnetic resonance imaging using established and new scoring systems. Ann Rheum Dis (2004) 1.56
Occupational handling of chemicals preceding Hodgkin's disease in men. Br Med J (1979) 1.56
Two year maintenance of efficacy and safety of infliximab in the treatment of ankylosing spondylitis. Ann Rheum Dis (2004) 1.53
Relation between drug treatment and cancer in hypertensives in the Swedish Trial in Old Patients with Hypertension 2: a 5-year, prospective, randomised, controlled trial. Lancet (2001) 1.52
Increased cancer risk in offspring of women with colorectal carcinoma: a Swedish register-based cohort study. Cancer (2000) 1.52